NETcure-Shine New Light on NET Therapy

Martin Gotthardt, PhD

Year: 2019
Institution: Radboud University Nijmegen Medical Centre
Country: Netherlands
Award Type: Investigator
NET Type: Multiple
Science Type: Clinical

General Description

The lack of reliable, widely-available models is currently a major impediment to the development of new therapies for patients with pancreatic neuroendocrine tumors. This proposal to characterize a patient-derived xenograft will help researchers understand and utilize this exciting new resource.  Dr. Nakakura will characterize a patient-derived, xenograft model of pancreatic neuroendocrine cancer and continue efforts to develop and share other neuroendocrine cancer models.


Chamberlain CE, German MS, Yang K, Wang J, VanBrocklin H, Regan M, Shokat KM, Ducker GS, Kim GE, Hann B, Donner DB, Warren RS, Venook AP, Bergsland EK, Lee D, Wang Y, Nakakura EK. A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors. Mol Cancer Ther. 2018 Dec;17(12):2702-2709. doi: 10.1158/1535-7163.MCT-17-1204. Epub 2018 Sep 25.